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Isolation and characterization of equine
native MSC populations
Cristina L. Esteves1,4*, Tara A. Sheldrake1, Simone P. Mesquita1, Juan J. Pesántez1, Timothy Menghini1,
Lucy Dawson1, Bruno Péault2,3 and F. Xavier Donadeu1
Abstract
Background: In contrast to humans in which mesenchymal stem/stromal cell (MSC) therapies are still largely in
the clinical trial phase, MSCs have been used therapeutically in horses for over 15 years, thus constituting a valuable
preclinical model for humans. In human tissues, MSCs have been shown to originate from perivascular cells, namely
pericytes and adventitial cells, which are identified by the presence of the cell surface markers CD146 and CD34,
respectively. In contrast, the origin of MSCs in equine tissues has not been established, preventing the isolation
and culture of defined cell populations in that species. Moreover, a comparison between perivascular CD146+
and CD34+ cell populations has not been performed in any species.
Methods: Immunohistochemistry was used to identify adventitial cells (CD34+) and pericytes (CD146+) and to
determine their localization in relation to MSCs in equine tissues. Isolation of CD34+ (CD34+/CD146–/CD144–/CD45–)
and CD146+ (CD146+/CD34–/CD144–/CD45–) cell fractions from equine adipose tissue was achieved by fluorescence-
activated cell sorting. The isolated cell fractions were cultured and analyzed for the expression of MSC markers, using
qPCR and flow cytometry, and for the ability to undergo trilineage differentiation. Angiogenic properties were analyzed
in vivo using a chorioallantoic membrane (CAM) assay.
Results: Both CD34+ and CD146+ cells displayed typical MSC features, namely growth in uncoated tissue culture
dishes, clonal growth when seeded at low density, expression of typical MSC markers, and multipotency shown by
the capacity for trilineage differentiation. Of note, CD146+ cells were distinctly angiogenic compared with CD34+ and
non-sorted cells (conventional MSCs), demonstrated by the induction of blood vessels in a CAM assay, expression of
elevated levels of VEGFA and ANGPT1, and association with vascular networks in cocultures with endothelial cells,
indicating that CD146+ cells maintain a pericyte phenotype in culture.
Conclusion: This study reports for the first time the successful isolation and culture of CD146+ and CD34+ cell
populations from equine tissues. Characterization of these cells evidenced their distinct properties and MSC-like
phenotype, and identified CD146+ cells as distinctly angiogenic, which may provide a novel source for enhanced
regenerative therapies.
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Background
Other than humans, horses are the species in which
interest in the use of mesenchymal stem/stromal cells
(MSCs) for regenerative medicine has been highest
[1–8]. Similar to humans, adipose tissue and bone
marrow have been the MSC sources of choice in the
horse, due to their relative ease of access and the
number of putative stem cells they contain [2, 9–13].
Indeed, MSCs have been safely applied clinically to
horses for well over a decade, now being an integral
component of equine health care worldwide which has
an estimated economic impact in the United States and
the United Kingdom of $102 billion and $10 billion per
annum, respectively. Importantly, given the similarities in
the types of natural injuries suffered by both humans and
horses, the US Food and Drug Administration [14] has
approved the use of horses as a preclinical model for
musculoskeletal conditions.
In regenerative medicine, cell preparations are applied
either as crude extracts or following expansion in cul-
ture to attain the desired amount of clinical cells. How-
ever, these preparations are heterogeneous in nature,
containing small and variable amounts of true stem cells
in addition to other, nonprecursor cell types which upon
transplantation into patients may reduce therapeutic ef-
ficacy. There is therefore a real need to identify specific
subsets of cells that have intrinsic regenerative capacity,
and to develop strategies to robustly isolate, expand in
culture, and characterize these cells. However, there is a
fundamental lack of understanding of the precise iden-
tity and defining features of MSCs in equine tissues,
which has thwarted efforts to selectively and efficiently
identify, harvest, and expand these cell subpopulations
in culture.
Studies in humans have identified two distinct perivas-
cular cell subpopulations, pericytes in capillaries and
microvessels [15, 16] and adventitial cells in arteries and
veins [17], as in vivo counterparts of MSCs [18, 19].
Pericytes and adventitial cells were isolated based on the
presence of the cell surface markers CD146 and CD34,
respectively, and were shown to maintain a typical MSC
phenotype in culture. Although tissue regeneration poten-
tial has been demonstrated for each individual cell sub-
population [20–22], the properties of CD146 and CD34
cells have not been compared directly.
Using fluorescence-activated cell sorting (FACS), we re-
port the isolation, culture, and characterization of equine
CD34+/CD146–/CD144–/CD45– (adventitial cells) and
CD146+/CD34–/CD144–/CD45– (pericytes) fractions—for
simplicity, referred to hereafter as CD34+ and CD146+, re-
spectively. Both cell types displayed an MSC phenotype,
although comparison with non-sorted cells (conventional
cultured MSCs) revealed differences in expression of
cell surface markers and angiogenic genes. Remarkably,
CD146+ cells were distinctly able to promote angiogen-




Tissue samples were obtained from a total of 15 adult
horses immediately post mortem at the School of
Veterinary Studies of the University of Edinburgh. All
animal procedures were carried out according to the
UK Home Office Animals (Scientific Procedures) Act
1986 with approval by the Ethical Review Committee,
University of Edinburgh, 60/4207. Adipose tissue was
kept for up to 24 h at 4 °C [23] before extraction of the
stromal vascular fraction (SVF).
Immunohistochemistry
Frozen samples, processed immediately after tissue
harvesting, were cut in a Leica CM1900 cryostat. For
staining, tissues were fixed in ice-cold acetone:metha-
nol (50:50) and antibodies were prepared in antibody
diluent (003118; Invitrogen-Thermo Fisher Scientific,
Paisley, UK). After staining, slides were mounted in Fluor-
oshield with 4′,6-diamidino-2-phenylindole (DAPI;F6057;
Sigma, St Louis, MO, USA). Primary antibodies used were
CD146-FITC (MCA2141F; AbD Serotec-BioRad, Kidling-
ton, UK), CD144 (AHP628Z; AbD Serotec-BioRad), NG2
(MAB2585; R&D Systems, Minneapolis, MN, USA),
αSMA (ab5694; AbCam, Cambridge, UK), CD29 (303015;
BioLegend, San Diego, CA, USA), CD44 (AbD Serotec-
BioRad), and CD34 (21270341S; ImmunoTools, Frie-
soythe, Germany). Isotype controls were IgG1-FITC
(MCA928F; AbD Serotec-BioRad), IgG1 (MAB002;
R&D Systems), IgG1κ (400101; BioLegend), and IgG1
(21335011; ImmunoTools), all raised in mouse; and rabbit
IgG (PRABP01; AbD Serotec-BioRad). Secondary anti-
bodies were conjugated to AF488 (A11029), AF568
(A110037), and AF568 (A10042), all from Invitrogen-
Thermo Fisher Scientific. Micrographs were produced
using a Zeiss LSM710 confocal or Leica DMLB fluores-
cent microscope.
Cell extraction and culture
Extraction of the SVF from adipose tissue involved
mincing the tissue with scissors and digestion for
45 min with collagenase II (1 mg/ml; Gibco-Thermo
Fisher Scientific)/BSA (3.5%) at 37 °C under agitation
(100 rpm). Collagenase activity was stopped by addition
of DMEM with 20% FBS (Thermo Fisher Scientific) and
the lipid layer was removed after separation by gravity.
Samples were filtered and spun down to obtain the SVF,
which was further washed in PBS/FBS (5%) and treated
with red cell lysis buffer (Sigma-Aldrich). Cells were then
stained with appropriate antibodies for flow analysis or
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sorting, or seeded for expansion at 5000 cells/cm2 in
EGM-2 (Lonza, Slough, UK) which was replaced by
DMEM/FBS (20%) at the first cell passage. The doubling
time of non-sorted, CD34+, or CD146+ cultured cells was
calculated using the formula:
DT ¼ T ln2= ln Xe=Xbð Þ;
where T is the incubation time in days, Xb is the cell
number at the beginning of the incubation time, and Xe
is the cell number at the end of the incubation time. To
determine colony-forming unit fibroblasts (CFU-F), cells
were seeded at a density of 1, 5, and 25 cells/cm2 and
allowed to grow for 12 days. Colonies were visualized by
staining with crystal violet (0.5%) and counted. To ob-
tain endothelial cells, blood vessel sections were washed
with PBS and then filled with collagenase II solution
(1 mg/ml) before both ends of the vessel were ligated.
Following 45-min incubation at 37 °C, endothelial cells
were recovered and were cultured in EGM-2 endothelial
cell medium.
Flow cytometry and FACS
In order to isolate cell subpopulations, SVFs were
stained for 1 h on ice using primary antibodies against
CD144 (AHP628Z; AbD Serotec-BioRad), CD45-FITC
(MCA832F; BioRad), CD146-AF647 (MCA2141A647;
AbD Serotec-BioRad), and CD34-PE (4H11[APG]; Immu-
noTools) followed by incubation for 30 min on ice with
AF405-conjugated secondary antibody (ab175654; AbCam).
Isotype controls used (raised in mouse) were IgG1-
FITC (MCA928F; AbD serotec-BioRad), IgG1-AF647
(MCA928A647, AbD serotec-BioRad), and IgG1-PE
(21275514; ImmunoTools). Fluorescence minus one
(FMO) for CD146 was obtained with a mix of anti-
bodies against CD144, CD45, and CD34, and the mix
for CD34 FMO included CD144, CD45, and CD146.
DAPI was added to the samples 5 min before flow
analysis and was used to determine cell viability. Cells
were sorted on a BD FACSAria Fusion (BD Biosci-
ences, San Jose, CA, USA).
In order to analyze the immunophenotype of cultured
cells, non-sorted, CD34+, and CD146+ cells were har-
vested using accutase (SLBN3817V; Sigma). The staining
protocol was similar to that already described for FACS
and included primary antibodies to CD29 (303001; BioLe-
gend), CD44 (MCA1082GA; AbD serotec-BioRad), CD90
(554895; BD Biosciences), and CD105 (MCA1557T; AbD
serotec-BioRad), as well as the isotype controls mouse
IgG1κ (400101; BioLegend) and mouse IgG1 (MAB002:
R&D Systems). Secondary antibody was AF488-conjugated
(A11029; Invitrogen-Thermo Fisher Scientific), and Sytox
blue (S34857; Thermo Fisher Scientific) was used to deter-
mine cell viability. Samples were run on a BD LSR Fortessa
(BD Biosciences) and data were analyzed using BD
FACSDiva software version 8.0.1 or FlowJo (LLC,
Ashland, OR, USA).
RNA extraction and gene expression analyses
Cultured cells or freshly collected SVFs were harvested
in Trizol (15596-026; Invitrogen-Thermo Fisher Scien-
tific) and the concentration of total RNA was measured
using Nanodrop. RNA was reverse transcribed with
SuperScript III (18080-044; Invitrogen-Thermo Fisher
Scientific) and qPCR was performed using the SensiFAST
SYBR Lo-ROX kit (BIO-94020; Bioline, London, UK) in a
Stratagene machine. Primers were either designed by us
for CD144 (5′-TCTGCAGGACATCAATGACAAC-3′
and 5′-CTTCAG GCACGGCAAATACG-3′) and 18S
(5′-GCTGGCACCAGACTTG-3′ and 5′-GGGGAATC
AGGGTTCG-3′) or were based on previously reported
sequences [24]. Data were analyzed with MxPro soft-
ware and normalized to 18S.
Cell differentiation
Non-sorted, CD34+, and CD146+ cultured cells were dif-
ferentiated into adipocytes, chondrocytes, and osteocytes.
Briefly, for adipocyte differentiation, cells were grown until
70% confluency [25, 26] and induced in the presence of
dexamethasone (1 μm, D4902; Sigma Aldrich), 3-isobutyl-
1-methylxanthine (0.5 mM, 15879; Sigma Aldrich), insulin
(10 μg/ml, 19278; Sigma Aldrich), indomethacin (100 μM,
I8280; Sigma Aldrich), rabbit serum (7%), and fetal bovine
serum (3%). Cells were differentiated for 5 days with
medium being changed twice. Chondrogenesis and
osteogenesis were performed using StemPro differenti-
ation kits following the manufacturer’s instructions for
18 days (A10071-01 and A10072-01, respectively; Life
technologies-Thermo Fisher Scientific). Adipocytes
were stained with Oil red O (O0625; Sigma-Aldrich) as
described before [27]. In brief, cells were first fixed in
paraformaldehyde (PFA; 4%) for 3 min, rinsed with 60%
isopropanol, and stained with Oil red O (0.1%) for
10 min and then rinsed with isopropanol again and
washed with water. Chondrocyte pellets were embed-
ded in Histogel (HG-4000; Invitrogen-Thermo Fisher
Scientific) and paraffined, and then cut at 8 μm thick-
ness. Slides were dewaxed and rehydrated. Alcian blue
solution (1%) was added to the slide and incubated
overnight. After washing, Neutral red (1%) solution was
added and absolute ethanol and xylene were used to
dehydrate the slides that were mounted with pertex.
For osteocyte staining, cells were washed with PBS,
fixed with PFA (4%) for 15 min, and stored in PBS at
4 °C. After washing the cells with water, Alizarin Red S
(A5533; Sigma-Aldrich) was added. The plate was incu-
bated at room temperature in the dark for 10 min and
washed with water. Alkaline phosphatase activity was
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determined in differentiated cells using a commercial
kit (86R-1KT; Sigma-Aldrich) according to the manu-
facturer’s specifications. Briefly, cells were washed twice
with PBS, then fixed with PFA-citrate acetate buffer for
30 sec and washed again with PBS, to which the alka-
line–dye mixture was added for the reaction to proceed
with wells protected from light, and then washed with
water. Negative controls were produced with nondiffer-
entiated cells in culture and micrographs were taken on
an Axiovert 25 inverted microscope (Zeiss, Oberko-
chen, Germany).
Angiogenesis assays
The chorioallantoic membrane (CAM) assay was used to
assess in vivo angiogenic potential of non-sorted cells
and sorted CD34+ and CD146+ cells. Fertilized eggs
(NovoGen, Le Foeil, France) were cleaned with ethanol
(70%) and incubated at 37 °C in 60% humidity. Three
days later, 2 ml of albumen was aspirated from the egg
with a syringe and a window was created which was cov-
ered again and returned to incubation. On day 8 of incu-
bation, polypropylene rings were placed on the CAM
and cells (75,000 cells) or PBS were placed in the center
of the ring, as described previously [28, 29]. The eggs
were incubated for a further 2 days, when images from
each ring were taken using the Zeiss AXIO ZoomV16
microscope at 40×. Binary images were generated by Image
J and angiogenesis was quantified using AngioSys2.0
software (Cellworks, Buckingham, UK).
For in vitro angiogenesis experiments, CD146+ and
endothelial cells were stained with PKH26 (20 μM) and
PKH67 (20 μM) (both from Sigma-Aldrich), producing
red and green fluorescence signals, respectively. Once
labeled, cells were resuspended in EGM-2 medium and
seeded on ibiTreat μ-Slides (IB-81506; Thistle Scientific)
coated with matrigel. Pictures were taken using a Zeiss
Live Cell Observer/Deconvolution system.
Statistical analysis
Results are shown as mean ± standard error of the mean,
and were analyzed by one-way or two-way ANOVA
followed by comparison among means with Tukey test
using GraphPad Prim 6.0 software (GraphPad Software,
La Jolla, CA, USA). Significance was set at p < 0.05.
Results
CD146 and CD34 mark perivascular cells and colocalize
with MSC markers in equine tissues
We began by testing the cross-reactivity of cell surface
marker antibodies in equine tissues. In human tissues,
CD146 (MCAM, Muc18) has been commonly used to
identify pericytes surrounding small blood vessels [16, 30].
Similarly, in equine tissues including adipose, testis, and
skeletal muscle, CD146 had an abluminal location to the
endothelial marker CD144 (VE-cadherin); importantly,
CD144 was not present in CD146+ cells, indicating that
these corresponded to pericytes (Fig. 1 a–c). Other an-
tigens known to be expressed by pericytes, namely NG2
(CSPG4), αSMA (ACTA1), and CD146, colocalized in
the tissues analyzed (Fig. 1d, e). Moreover, the MSC
markers CD29 and CD44 were also detected perivascu-
larly, costaining with NG2 and CD146, respectively
(Fig. 1f, g). Adventitial cells were identified by CD34+
staining in the outer layer of larger blood vessels, which
followed a pattern similar to that of the MSC marker
CD44 (Fig. 1h, i). Overall, these results showed that
pericytes and adventitial cells colocalize perivascularly
with MSC markers in horse tissues, consistent with the
notion in the human that perivascular cells give rise to
MSCs in culture [15, 17].
Isolation of CD146+ and CD34+ cells from equine adipose
tissue
There are no reports on the isolation of perivascular
cells in the horse. Extraction of the stromal vascular
fraction (SVF) from adipose tissue by standard collage-
nase digestion resulted in an adipocyte-free preparation
(around 300,000 cells/g tissue) containing different cell
types including many erythrocytes. Thus, an essential
step in the preparation of samples for FACS was incu-
bation with red blood cell lysis buffer, because high
numbers of erythrocytes could interfere with antibody
staining, flow analysis, and cell sorting. Selection of an
antibody panel for FACS was based on IHC validation
(Fig. 1) as well as optimization by flow cytometry using
equine adipose, testes, and peripheral blood mono-
nuclear cell samples (data not shown). FACS of CD34+
and CD146+ subpopulations from adipose SVF extracts
sequentially involved: selection of single events (single
cells) plotted as forward scatter area vs forward scatter
height (FSC-A vs FSC-H; Fig. 2A), visualized in the dot-
plot of FSC-A vs side scatter area (SSC-A; Fig. 2B); se-
lection of DAPI-negative (live) cells (Fig. 2C); sorting
out of CD144+ endothelial cells (Fig. 2D); gating of
CD45-FITC-negative cells (Fig. 2E); and selection of
cells positive for CD34-PE and CD146-AF647 (Fig. 2F)
to separately obtain CD45–/CD144–/CD146–/CD34+
(CD34+ cells; 0.6 ± 0.4% of total) and CD45–/CD144–/
CD34–/CD146+ cells (CD146+ cells; 1.9 ± 0.7% of total).
Antibody isotypes or AF405-linked secondary anti-
bodies were used as controls (Fig. 2c2, c4, c5). CD34+
and CD146+ cells were then cultured and characterized.
CD146+ and CD34+ cells show similar growth in culture
Non-sorted cells (conventional MSCs) and sorted CD34+
and CD146+ cells showed similar morphology in culture
(Fig. 3a). Cells were passaged and seeded at a density of
5000 cells/cm2, producing similar doubling times between
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passages 2 and 6 (Fig. 3b). CFU-F (Fig. 3c) were quantified
by seeding cells at low densities (1, 5, and 25 cells/cm2)
and staining colonies with crystal violet 12 days later. In
our hands, a seeding density of 5 cells/cm2 was optimal
and was used for CFU-F quantification, with no significant
differences being found between the three cell types
(Fig. 3d).
Expression of cell surface markers by CD146+ and CD34+
cells in culture
Based on qPCR analyses, CD146+ cells expressed the
highest levels of CD146 throughout culture, around 3-
fold higher than non-sorted cells (p < 0.05; Fig. 4a),
showing that the isolation process was effective. CD146
mRNA was detected in some CD34+ cell samples but at
markedly reduced levels compared with CD146+ cells
(27-fold lower in average), which may correspond to a
transitional minority subpopulation between pericyte
and adventitial cells as described in humans [30].
Expression of CD34 was variable and substantial only
in CD34+ cells at passages 1/2 and then decreased
(Fig. 4b; p < 0.05), as is known to occur in cells in
culture [31, 32]. CD34 was absent in the CD146+ cells,
except for very low levels in one of the samples. CD144
was detected in all non-sorted samples (Fig. 4c) at
lower values than in the initial SVF crude extract (data
not shown). CD144 was expressed at much lower levels
(around 13-fold) in CD34+ cells and was occasionally
Fig. 1 Immunohistochemistry of pericyte, adventitial cell, and MSC markers in equine tissues. a–c Pericytes stained for CD146 surrounding CD144
+ endothelial cells in adipose tissue (a), testis (b), and skeletal muscle (c). d, e Dual staining (right panel) with the pericyte markers NG2 and
CD146 (d) or NG2 and αSMA (e) in adipose tissue and testis, respectively. f, g Colocalization (right panel) of the MSC and pericyte markers CD29
and NG2 (f) and CD44 and CD146 (g) in adipose tissue, respectively. d–g Individual staining is shown (left and middle panels). h, i Immunodetection of
the adventitial cell marker CD34 (h) and the MSC marker CD44 (i) in the outer layer of blood vessels (arrows) in adipose tissue. 4′,6-Diamidino-
2-phenylindole (DAPI) was used to stain cell nuclei. White scale bars = 10 μm
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detected, at negligible levels, in CD146+ cells. CD45
was not detected except in one of the non-sorted
preparations at passages 1/2 (data not shown), an ob-
servation that we have occasionally made in other
non-sorted samples and which has also been reported
by others [33].
CD146+ and CD34+ cells express MSC markers
qPCR analysis demonstrated that MSC markers were
present in both CD34+ and CD146+ cells in culture
(Fig. 5). Indeed, CD73, CD90, and CD105 mRNA was
detected in both cell types as well as in non-sorted cells
up to at least passage 4 (Fig. 5a). Expression of these
Fig. 2 Isolation of CD34+ and CD146+ cells from adipose SVF. a, b Events displayed as FSC-A vs FSC-H to select singlets (a) were further gated to
exclude cell fragments or noncellular material (b). c–e Sequence of plots showing selection of DAPI-negative, CD144(AF405)-negative, and
CD45(FITC)-negative cells to obtain live, endothelial-negative, and hematopoietic-negative fractions, respectively. (c1–c4) Dot-plots for CD144
(c1, c2) and CD45 (c3, c4) controls showing unstained cells (c1, c3) and secondary antibody conjugated to AF405 (c2) or isotype conjugated to
FITC (c4). f Double-plot displaying CD34+ (Q1) and CD146+ (Q4) cell subpopulations and respective isotype controls (c5) conjugated to PE and
AF647, respectively. Filters used: 450/50 for AF405, 525/50 for FITC, 586/15 for PE, and 670/30 for AF647. FSC-A forward scatter area,
FSC-H forward scatter height, SSC-A side scatter area
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genes was lower in CD146+ cells than in non-sorted
cells at all passages (p < 0.05), except for CD90 at
passages 3/4. Moreover, apart from higher (p < 0.05)
expression of CD105 in CD34+ cells than CD146+
cells at passages 1/2, there were no differences in ex-
pression of the three MSC markers between CD34+
and the other two cell types.
In agreement with the qPCR results, all MSC markers
tested by flow cytometry (CD29, CD44, CD90, and
CD105) were present in CD34+ and CD146+ cells (Fig. 5b).
Importantly, for all markers the antibody-positive cells
produced distinct peaks from the isotype controls, indi-
cating that the great majority of the cells in the samples
expressed the respective maker. However, differences
were observed in mean fluorescence intensity (MFI),
suggesting differences in antigen level between cell
types (Fig. 5c). In general, MFI values for MSC markers
were lower in CD146+ cells than in non-sorted and
CD34+ cells, although these differences were not sig-
nificant in the case of CD44.
CD146+ and CD34+ cells are multipotent
Similar to non-sorted cells, both CD34+ and CD146+
populations were capable of trilineage differentiation
(Fig. 6). Upon culture in adipogenic media, all three cell
types became round in morphology and accumulated
lipid vesicles, as shown by Oil red O staining in the cyto-
plasm (Fig. 6a). Chondrogenesis and osteogenesis were
also observed in the three cell types, with Alcian blue
coloring glycosaminoglycanss in chondrocyte pellets
counterstained with Neutral red (Fig. 6b). Osteocytes
displayed staining of calcium deposits by Alizarin Red
and were also alkaline phosphatase-positive (Fig. 6c).
These results indeed show that multipotency is main-
tained by CD146+ and CD34+ cells in culture.
Equine CD146+ cells promote angiogenesis
Angiogenesis is crucial in tissue regeneration and can be
reportedly stimulated by MSCs [34]. For this reason, we
determined the relative expression of the angiogenic
factors VEGFA and ANGPT1 by CD34+, CD146+, and
non-sorted cells, as well as the capacity of each cell type
Fig. 3 Growth of sorted cells in culture. a Micrographs showing
similar morphology for non-sorted, CD34+, and CD146+ cells grown
in DMEM supplemented with 20% FBS and passaged at a density of
5000 cells/cm2. b Doubling times (days) for non-sorted, CD34+, and
CD146+ cells at passages 2–3 (P2-3) and 5–6 (P5-6). n≥ 5; mean ±
SEM. c, d Colonies obtained from cells grown at low density (5 cells/
cm2) were stained with crystal violet (c) and CFU-F were counted
(d). n ≥ 3; mean ± SEM. CFU-F colony-forming unit fibroblasts
Fig. 4 Gene expression analysis of non-sorted, CD34+, and CD146+
cultured cells. mRNA levels were quantified by qPCR using primers
for a CD146 (pericyte marker), b CD34 (adventitial cell), and c CD144
(endothelial cells) in non-sorted (light gray), CD34+ (dark gray) and
CD146+ (black) cells at passage 1 or 2 (P1/2), 3 or 4 (P3/4), and 7 or 8
(P7/8). n = 3–6; mean ± SEM. *p < 0.05, **p < 0.001 between means.
AU arbitrary units, ND not detected
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to promote angiogenesis in vivo (Fig. 7). The three cell
types expressed VEGFA and ANGPT1, but levels of the
two genes were significantly higher in CD146+ cells than
in non-sorted or CD34+ cells (Fig. 7a). We then tested an-
giogenic activity using the chick embryo chorioallantoic
membrane (CAM) assay, a method that has been exten-
sively used for angiogenic assays in tumor [28] and stem
cell [34–36] studies. The CAM is easily accessible and al-
lows quantification of angiogenesis in a large number of
samples simultaneously. In agreement with qPCR data, we
found that CD146+ cells distinctly promoted angiogenesis
in vivo, as shown by significant increases (relative to PBS
control) in blood vessel branching and total vessel length
in membranes exposed to CD146+ cells compared with
non-sorted and CD34+ cells (Fig. 7b, c). In addition, cocul-
ture experiments (Fig. 7d) demonstrated the association
between CD146+ cells and endothelial cells on matrigel,
suggestive of network stabilization by CD146+ as occurs
naturally in tissues, and indicating that these cells main-
tained their native properties in culture.
Discussion
Despite the enormous interest in the use of MSC ther-
apies in both humans and horses, and the impressive
amount of literature devoted to this topic over the last
decade, cell heterogeneity in clinical MSC preparations
has significantly hindered the full exploitation of these
therapies. The identification of two distinct perivascular cell
subpopulations, based on the expression of CD146 and
CD34, as precursors of MSCs in human tissues [15, 17]
provided a significant step forward toward new therapies
with increased clinical efficacy. However, studies using
defined cell subpopulations (as opposed to traditional
heterogeneous MSC preparations) in the horse are lack-
ing, largely a consequence of the difficulty in translating
cell isolation procedures developed for human cells to
other species and the limited availability of species-specific
antibodies. Here, we have successfully established for the
first time a methodology to isolate perivascular CD34
+/CD146–/CD45–/CD144– and CD146+/CD34–/CD45–/
CD144– populations in the horse. We report the successful
Fig. 5 Isolated CD146+ and CD34+ cells express MSC markers. qPCR measurements (a) of CD73 (left), CD90 (middle), and CD105 (right) of non-sorted
(light gray), CD34+ (dark gray), and CD146+ (black) cells analyzed at passage 1 or 2 (P1/2) and 3 or 4 (P3/4). Flow cytometry histograms (b) displaying
fluorescence intensity (AF488 conjugated to the secondary antibody) vs event counts (corresponding to number of cells) and showing displacement
of non-sorted (light gray), CD34+ (dark gray), and CD146+ (black) cultured cells stained with antibodies CD29, CD44, CD90, and CD105 in comparison
with the isotype controls (very light gray, on left). Data were obtained from P3 to P5. c Quantification of the flow signals depicted in bar graphs as mean
fluorescence intensity (MFI) of non-sorted (light gray), CD34+ (dark gray), and CD146+ (black). n ≥ 3; mean ± SEM. *p < 0.05, **p < 0.001,
***p < 0.0001 between means. AU arbitrary units
Esteves et al. Stem Cell Research & Therapy  (2017) 8:80 Page 8 of 12
expansion of these cells in culture as well as the
characterization of their properties relative to non-
sorted MSC populations.
The observation that CD146 and CD34 have a perivas-
cular location in different equine tissues which coincides
with that of established MSC markers is consistent with
the notion that pericytes and adventitial cells are native
MSC precursors [15, 17, 37], thus extending previous
observations in humans to the horse. Our finding that
CD146 is robustly maintained by sorted CD146+ cells in
culture is in agreement with two previous PCR [38] and
flow cytometry [39] studies reporting the presence of
CD146 in equine MSCs. In contrast, expression of CD34
in CD34+ cells was variable and quickly decreased upon
culture, as reported for other cells [31, 32]. This may
account in part for the fact that CD34 has only occa-
sionally been detected by PCR in equine MSCs [38, 40],
and for the difficulty so far in identifying CD34 anti-
bodies cross-reacting with equine cells. Indeed, in the
present study only one of the five CD34 antibodies
tested could be used successfully with equine samples.
CD34+ and CD146+ populations displayed typical MSC
properties, namely adherence to uncoated tissue-culture
dishes, inclusion of CFU-F, and trilineage differenti-
ation, in addition to expressing classical MSC markers
both in tissues and during culture. Importantly, flow
cytometry analyses indicated that these markers were
present in almost all cells within the two sorted sub-
populations, although corresponding MFI and mRNA
levels were in general lower in CD146+ cells than in
the other cell types analyzed. This could be attributed
to loss of cell surface marker expression during the
time in culture. Another possibility is that cell con-
taminants such as hematopoietic and/or endothelial
cells, which can also express MSC markers [41–45],
contributed to the relatively higher expression of these
markers, particularly in non-sorted cell cultures. Con-
sistent with this assumption, the single non-sorted cell
sample with detectable CD45 mRNA also displayed
the highest values for CD90 and CD105 and, in
addition, the endothelial marker CD144 was also
expressed by non-sorted cells in culture. Regardless of
the reasons for these differences, the results indicate
that CD146+ cells are distinct from non-sorted and
CD34+ cells in equine adipose tissue.
Angiogenesis has a critical contribution to tissue regen-
eration by allowing supply of oxygen, nutrients, and im-
mune cells and clearing of metabolic products [46, 47].
Because of their anatomical location, pericytes and adven-
titial cells are uniquely positioned to regulate angiogenesis
both by direct contact with endothelial cells and by para-
crine production of angiogenic factors [23, 48, 49]. Using
the CAM model, we showed that, under our experimental
conditions, CD146+ cells, but not non-sorted or CD34+
cells, were able to promote angiogenesis in vivo, pre-
sumably due in part to their higher expression of the
angiogenic factors VEGFA and ANGPT1. In the horse,
two publications [50, 51] reported on the angiogenic
activity of MSCs, specifically on the stimulation of vas-
cular network formation by peripheral blood-derived
MSCs in culture [50] and the proangiogenic effects of
adipose MSC-derived membrane vesicles in rat aortic
rings and scratch assays [51]. However, in those reports
the effects of MSCs in vivo were not determined and,
in addition, the specific subpopulations involved in the
responses observed in vitro were not identified. Limited
studies in humans have gone further to determine the
angiogenic effects of isolated CD146+ or CD34+ popu-
lations in vivo using animal models. In particular, human
CD146+ cells were shown to promote angiogenesis after
transplantation into SCID/mdx mouse muscle [52] and in
SCID mouse ischemic myocardium [22]. Moreover, im-
provement of angiogenesis in ischemia was reported in re-
sponse to CD34+/CD31– cells obtained from human
saphenous vena; however, other cell types in these prepa-
rations could have contributed to the effects observed
[53]. Importantly, the effects of CD146+ and CD34+ on
Fig. 6 Isolated CD146+ and CD34+ cells are multipotent. Micrographs
showing differentiation of non-sorted (left), CD34+ (middle), and CD146+
cells (right) into adipocytes (a), chondrocytes (b), and osteocytes
(c). a Adipocytes were stained with Oil red O, showing the lipid
content in the cells (red). b Histological sections (8 μm) of differentiated
chondrocyte pellets were stained with Alcian blue to detect
glycosaminoglycans and counterstained with Neutral red. c Alizarin
Red S and the alkaline phosphatase activity assay were used to
stain osteocytes differentiated for 19 days, resulting in staining of
calcium deposits (red, upper row and purple, lower row, respectively).
Black scale bars = 50 μm
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angiogenesis had so far not been directly compared in any
species. Our results using the equine model show CD146+
cells to be distinctly angiogenic compared with CD34+
cells and suggest that the former subpopulation is a pri-
mary contributor to the proangiogenic properties attrib-
uted to MSCs.
Conclusions
Here we report the isolation and characterization of
CD146+ and CD34+ cell subpopulations from equine
adipose tissue. The results showed that although both
subpopulations display a MSC-like phenotype, CD146+
cells are distinctly angiogenic in vivo, indicating CD146+
cells maintain a pericyte phenotype during culture.
Based on these results, the marker panels currently used
to define MSC populations with regenerative potential
may have to be reassessed, because high levels of
CD146, but not the classical MSC markers, were associ-
ated with angiogenic capacity in this study. Our results
also underscore the potential advantages of using
defined cell populations over standard heterogeneous
MSC preparations for therapy. Angiogenesis is indeed a
major component of tissue repair and the use of CD146+
cell subpopulations may be particularly beneficial in the
Fig. 7 CD146+ cells are angiogenic. a Transcript levels of angiogenic factors VEGFA and ANGPT1 in non-sorted (light gray), CD34+ (dark gray), and
CD146+ (black) cells, quantified by qPCR. b CAM micrographs obtained at 40× magnification showing formation of blood vessel plexus at 2 days
following incubation with PBS control (left), non-sorted (middle left), CD34+ (middle right), and CD146+ (right) cells. c Quantification of the CAM
blood vessel plexus using AngioSys2.1 software as fold variation in blood vessel branching (left) and blood vessel total length (right) over PBS-
treated controls. Non-sorted (light gray), CD34+ (dark gray), and CD146+ (black) cells. d Micrographs of in vitro cocultures of equine endothelial
(green, labeled with PKH26; 20 μM) and CD146+ (red, labeled with PKH67; 20 μM) cells seeded on matrigel, showing close apposition of CD146+
cells to the endothelial network (white arrows). n ≥ 3 for qPCR, n ≥ 12 for CAM experiments; mean ± SEM. *p < 0.05, **p < 0.001, ***p < 0.0001,
differences between different cell types; ###p < 0.0001, difference between CAM incubated with CD146+ cells and with PBS (control). AU
arbitrary units
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future to improve the efficacy of regenerative treatments
both in horses and humans.
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